Important Safety Information for VECTICAL ® (calcitriol) Ointment
Indication: VECTICAL ® Ointment is indicated for the topical treatment of mild to moderate plaque psoriasis in adults 18 years and older. Adverse Events: In controlled clinical studies, the most commonly reported adverse reactions (≥ 3%) were lab test abnormality, urine abnormality, psoriasis, hypercalciuria, pruritus, and skin discomfort. Warnings/Precautions: The maximum weekly dose should not exceed 200 g. Avoid contact with eyes, lips and face. VECTICAL ® Ointment should be used with caution in patients receiving medications known to increase the serum calcium level, such as thiazide diuretics and in patients receiving calcium supplements or high doses of Vitamin D. If aberrations in parameters of calcium metabolism are noted discontinue VECTICAL ® Ointment until these normalize. Avoid excessive exposure of VECTICAL ® Ointment treated areas to either natural or artificial sunlight.
You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit /medwatch or call 1-800-FDA-1088 (1-800-332-1088).
Click here for Full Prescribing Information for VECTICAL ® Ointment
Patients requiring oral corticosteroids should be weaned slowly from systemic corticosteroid use after transferring to ADVAIR HFA. Prednisone reduction can be accomplished by reducing the daily prednisone dose by mg on a weekly basis during therapy with ADVAIR HFA. Lung function (mean forced expiratory volume in 1 second [FEV 1 ] or morning peak expiratory flow [AM PEF]), beta-agonist use, and asthma symptoms should be carefully monitored during withdrawal of oral corticosteroids. In addition, patients should be observed for signs and symptoms of adrenal insufficiency, such as fatigue, lassitude, weakness, nausea and vomiting, and hypotension.